Literature DB >> 28620833

Assessment of serum uric acid as risk factor for tauopathies.

Tommaso Schirinzi1,2, Giulia Di Lazzaro3, Vito Luigi Colona3, Paola Imbriani3, Mohammad Alwardat4, Giulia Maria Sancesario5, Alessandro Martorana3, Antonio Pisani3.   

Abstract

Low levels of serum uric acid (UA) are a risk factor for many neurodegenerative diseases but the role of UA in tauopathies has not been yet fully evaluated. In this study, we assessed the risk associated with serum UA levels in a large group of patients with tauopathies, either primary or secondary. The mean serum UA concentrations of 111 patients with tauopathies (TAU), including 41 with progressive supranuclear palsy (PSP), 45 with Alzheimer's disease (AD) and 25 with frontotemporal dementia (FTD) were compared to that of 130 controls (CTL). The association between serum UA and TAU condition, PSP, AD and FTD was calculated as odd ratio (OR) adjusted for age and gender. A cut-off value of serum UA was finally obtained to predict subjects at risk for TAU. The serum UA levels in TAU and PSP, AD and FTD subgroups were similar, and significantly lower than CTL. Linear regression revealed inverse relationships between UA and TAU (OR = 0.610), PSP (OR = 0.626), AD (OR = 0.685) and FTD (OR = 0.577). The cut-off value of 4.35 mg/dl (AUC = 0.655) discriminates TAU from CTL, although with poor specificity and sensitivity. Low concentrations of serum UA represent a common risk factor for different tauopathies (PSP, FTD and AD). These findings may represent a starting point for preventive strategies or novel therapeutic approaches in this group of severe neurodegenerative diseases.

Entities:  

Keywords:  Alzheimer’s disease; Frontotemporal dementia; Progressive supranuclear palsy; Tauopathies; Urate; Uric acid

Mesh:

Substances:

Year:  2017        PMID: 28620833     DOI: 10.1007/s00702-017-1743-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

Review 1.  The epidemiology of Parkinson's disease: risk factors and prevention.

Authors:  Alberto Ascherio; Michael A Schwarzschild
Journal:  Lancet Neurol       Date:  2016-10-11       Impact factor: 44.182

2.  Relationship between uric acid levels and progressive supranuclear palsy.

Authors:  David M Brody; Irene Litvan; Steve Warner; David E Riley; Deborah A Hall; Benzi M Kluger; David R Shprecher; Christopher R Cunningham
Journal:  Mov Disord       Date:  2016-02-18       Impact factor: 10.338

3.  Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action.

Authors:  Ting-Ge Zhu; Xiao-Xia Wang; Wei-Feng Luo; Qi-Lin Zhang; Ting-Ting Huang; Xing-Shun Xu; Chun-Feng Liu
Journal:  Neurosci Lett       Date:  2011-11-06       Impact factor: 3.046

Review 4.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

5.  Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment.

Authors:  Mircea Balasa; Raquel Sánchez-Valle; Anna Antonell; Beatriz Bosch; Jaume Olives; Lorena Rami; Magda Castellví; José Luis Molinuevo; Albert Lladó
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 6.  Urate in Parkinson's disease: more than a biomarker?

Authors:  Xiqun Chen; Guanhui Wu; Michael A Schwarzschild
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

7.  Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization.

Authors:  Serge Guerreiro; Aurélie Ponceau; Damien Toulorge; Elodie Martin; Daniel Alvarez-Fischer; Etienne C Hirsch; Patrick P Michel
Journal:  J Neurochem       Date:  2009-03-19       Impact factor: 5.372

8.  Serum uric acid levels in patients with Alzheimer's disease: a meta-analysis.

Authors:  Xueping Chen; Xiaoyan Guo; Rui Huang; Yongping Chen; Zhenzhen Zheng; Huifang Shang
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 9.  Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.

Authors:  Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude Wischik; Patrick R Hof
Journal:  Biomolecules       Date:  2016-01-06

Review 10.  Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?

Authors:  Seyedeh Maryam Alavi Naini; Nadia Soussi-Yanicostas
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

View more
  4 in total

1.  Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.

Authors:  Tommaso Schirinzi; Giulia Maria Sancesario; Giulia Di Lazzaro; Simona Scalise; Vito Luigi Colona; Paola Imbriani; Nicola Biagio Mercuri; Sergio Bernardini; Anthony E Lang; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2018-06-14       Impact factor: 3.575

2.  Hyperuricemia and dementia - a case-control study.

Authors:  Bettina Engel; Willy Gomm; Karl Broich; Wolfgang Maier; Klaus Weckbecker; Britta Haenisch
Journal:  BMC Neurol       Date:  2018-08-31       Impact factor: 2.474

3.  Serum Uric Acid and the Risk of Dementia: A Systematic Review and Meta-Analysis.

Authors:  Zhike Zhou; Shanshan Zhong; Yifan Liang; Xiaoqian Zhang; Rongwei Zhang; Kexin Kang; Huiling Qu; Ying Xu; Chuansheng Zhao; Mei Zhao
Journal:  Front Aging Neurosci       Date:  2021-02-25       Impact factor: 5.750

4.  Plasma Uric Acid Helps Predict Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis.

Authors:  Jiahui Tang; Yuan Yang; Zhenxiang Gong; Zehui Li; Lifang Huang; Fengfei Ding; Mao Liu; Min Zhang
Journal:  Front Neurol       Date:  2021-12-06       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.